Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
It is a phase II trial to explore the efficacy and safety of cisplatin plus capecitabine in
anthracycline and taxane-pretreated metastatic triple negative breast cancer patients.